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To evaluate the association of either propylthiouracil or methimazole treatment for hyperthyroidism during
pregnancy with congenital malformations, relevant studies were identified by searching Medline, PubMed,
the Cochrane Library and EMBASE.
We intended to include randomized controlled trials, but no such trials were identified. Thus, we included
cohort studies and case-control studies in this meta-analysis.
A total of 7 studies were included in the meta-analyses. The results revealed an increased risk of birth defects
among the group of pregnant women with hyperthyroidism treated with methimazole compared with the control
group (odds ratio 1.76, 95% confidence interval 1.47–2.10) or the non-exposed group (odds ratio 1.71, 95%
confidence interval 1.39–2.10). A maternal shift between methimazole and propylthiouracil was associated with an
increased odds ratio of birth defects (odds ratio 1.88, 95% confidence interval 1.27–2.77). An equal risk of birth
defects was observed between the group of pregnant women with hyperthyroidism treated with propylthiouracil
and the non-exposed group (odds ratio 1.18, 95% confidence interval 0.97–1.42). There was only a slight trend
towards an increased risk of congenital malformations in infants whose mothers were treated with propylthiouracil
compared with in infants whose mothers were healthy controls (odds ratio 1.29, 95% confidence interval 1.07–1.55).
The children of women receiving methimazole treatment showed an increased risk of adverse fetal outcomes
relative to those of mothers receiving propylthiouracil treatment.
We found that propylthiouracil was a safer choice for treating pregnant women with hyperthyroidism according
to the risk of birth defects but that a shift between methimazole and propylthiouracil failed to provide protection
against birth defects.
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’ INTRODUCTION
Hyperthyroidism during pregnancy is uncommon, affecting
approximately 1 in 500 pregnancies (1). Overt hyperthyroidism
has well-documented adverse impacts on pregnancy outcomes,
such as preterm birth, congenital anomalies and pre-eclampsia
(2–4). Therefore, despite its rarity, proper management of
hyperthyroidism during pregnancy is of utmost importance.
Medical therapy is preferred by most authorities because
radioiodine is contra-indicated and because thyroidectomy
requires pre-treatment with antithyroid drugs and may be
complicated by surgical adverse effects (5). The available
antithyroid drugs (ATDs) are propylthiouracil (PTU) and
methimazole (MMI)/carbimazole (CZ). These drugs are
equivalent in terms of their efficacy for the treatment of
clinical hyperthyroidism (6). Concerning hyperthyroidism
during pregnancy, some reports suggest an association
between a specific congenital malformation (MMI embryo-
pathy) and prenatal exposure to MMI (7). The specific
malformation pattern related to prenatal MMI exposure
consists of choanal and esophageal atresia, scalp defects,
minor facial anomalies and psychomotor delay (8). The
reported facial anomalies typically include upward slanted
palpebral fissures, arched flared eyebrows and a small nose
with a broad bridge (9). A recent study conducted by
Anderson et al. demonstrated that ventricular septal defect
(VSD) is another component of MMI embryopathy (10).
Compared with non-exposure, exposure of children to MMI/
CMZ during early pregnancy (up to and including gesta-
tional week 10) is associated with an increased risk of VSD.
PTU may be safer than MMI, and PTU should be considered
as the first-line agent for the treatment of hyperthyroidism
during pregnancy (11). In contrast, other studies have shown
an equal risk of birth defects among pregnant women with
hyperthyroidism treated with PTU or with MMI (12), and
several major birth defects have been observed in theDOI: 10.6061/clinics/2015(06)12
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offspring of women treated with PTU (13). Unilateral kidney
agenesis and malformations of the face and neck region have
been associated with in utero exposure to PTU. In a case-
control study conducted by Clementi et al., PTU exposure
was significantly associated with an increased risk of situs
inversus, with or without dextrocardia (6). Recent animal
studies have demonstrated that PTU is teratogenic during
the late blastula, gastrulation and neurulation stages. PTU
can alter ciliary-driven flow and can disrupt the normal
genetic program involved in left-right axis determination
(14). Thus, there is no consensus regarding the best method
of therapy for hyperthyroidism during pregnancy. In this
study, we evaluated the association of either PTU or MMI
treatment for hyperthyroidism during pregnancy with
congenital malformations and conducted a systematic
review.
’ METHODS
Literature search and study selection
Relevant studies published until July 2014 were identified
by searching Medline, PubMed, the Cochrane Library and
EMBASE. The applied search criteria were related to thyroid
function and pregnancy outcomes. Specifically, the following
search items were used: thyroid*, hyperthyr*, Graves’
disease, PTU, propylthiouracil, MMI, methimazole, congeni-
tal malformation, birth defect and congenital anomalies.
There were no language limitations for the initial search.
Randomized controlled trials (RCTs), cohort studies and
case-control studies were included. Data on the effects of
combinational therapy were excluded.
Data extraction
The titles and the abstracts of the articles were indepen-
dently screened by two reviewers (Li X and Zhou L). The
articles to be included for full-text screening were compared
during a consensus meeting. In cases of disagreement, a
third reviewer (Ma JL) was consulted regarding the decision
about inclusion or exclusion for full-text evaluation. Articles
that did not contribute to the resolution of our research
questions after full-text evaluation were excluded.
Hyperthyroidism was defined as a low TSH level accom-
panied by a high free T4 level. After a consensus was
achieved, the remaining articles were included for critical
appraisal and were independently assessed by two
reviewers. Articles (RCT studies) were judged on scientific
quality according to the CONSORTand STROBE statements
(15,16).
Data analysis and statistical methods
The significance of each pooled odds ratio (OR) was
determined using a Z-test, in which po0.05 was considered
to indicate a significant difference. The w2-based Q statistical
test was employed for the assessment of between-study
heterogeneity, which was considered to be significant at
po0.1. In the analyses, if heterogeneity was low, then we
used a fixed effects model; otherwise, we applied a random
effects model. Review Manager 5.3 software (available from
Cochrane) was used to perform the meta-analyses.
’ RESULTS
Figure 1 shows the selection process after the search. Of the 7
articles included in this systematic review, 6 reported on MMI
use, 6 reported on PTU use and 2 reported on shifts between
MMI and PTU. The patients in the included studies were
pregnant womenwith hyperthyroidismwho required treatment
with antithyroid medication to maintain their thyroid hormone
levels within the normal range. All controls were pregnant
women who either exhibited euthyroidism or presented with
hyperthyroidism that was observed late in pregnancy; the latter
group of patients delivered before therapy and did not require
any antithyroid medication therapy (12). The characteristics of
the included articles are reported in Table 1.
The effect of PTU use on congenital malformations
A total of 7 studies reported on congenital malformations
after exposure to PTU. Compared with healthy pregnant
women, only one study showed an increased risk of
congenital malformations in pregnant women treated with
PTU (17). Three other studies did not detect any difference in
the congenital malformation rate (13,18,19). A meta-analysis
of these four studies concerning the association of exposure to
PTU with congenital malformations resulted in a pooled OR
of 1.29, with a 95% CI of 1.07–1.55, indicating a mild difference
(Figure 2A). We further compared the risk of congenital
malformations in pregnant women exposed to PTU with that
in women who were not exposed to any ATD during
pregnancy. The pregnant women in the non-ATD-exposed
group either exhibited euthyroidism throughout pregnancy,
thus requiring no medication, or presented with hyperthyr-
oidism that was observed late in pregnancy. The latter group
of patients delivered before therapy. There was no statistically
significant association between exposure to PTU and the risk of
birth defects (pooled OR 1.18, 95% CI 0.97–1.42) (Figure 2B).
The effect of MMI use on congenital malformations
As shown in Figure 3A, six studies reported on congenital
malformations after exposure to MMI. Three studies showed
an increased risk of congenital malformations in the group of
pregnant women treated with MMI compared with the
control group (11,17,20). Three other studies did not detect
any difference in the congenital malformation rate (12,13,18).
A meta-analysis of these six studies concerning the associa-
tion of exposure to MMI with congenital malformations
resulted in a pooled OR of 1.76, with a 95% CI of 1.47–2.10,
indicating a significant difference. Even compared with
women with hyperthyroidism who were not exposed to
any ATD during pregnancy, there was a significantly
increased risk of birth defects in women exposed to MMI
(pooled OR 1.71, 95% CI 1.39–2.10) (Figure 3B).
The effect of shifts between MMI and PTU use on
congenital malformations
As shown in Figure 4, two studies reported on congenital
malformations after shifting between MMI and PTU. Both
studies showed an increased risk of congenital malforma-
tions in pregnant women whose treatment shifted between
MMI and PTU compared with the controls (13,17). A meta-
analysis of these two studies resulted in a pooled OR of 1.88,
with a 95% CI of 1.27–2.77, indicating a significant difference.
The effect of antithyroid drugs on
congenital malformations
As shown in Figure 5, five studies reported on congenital
malformations after exposure to PTU or MMI. A meta-
analysis of these five studies resulted in a pooled OR of 0.73,
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with a 95% CI of 0.56–0.96, indicating that PTU was a safer
choice with respect to the risk of birth defects among
pregnant women with hyperthyroidism.
’ DISCUSSION
Several studies have linked hyperthyroidism during
pregnancy with an increased risk of congenital anomalies.
However, the evidence regarding the impact of ATDs such as
PTU and MMI on pregnancy outcomes remains controver-
sial. The preferred ATD during pregnancy in the USA is PTU,
whereas in Europe, it is MMI (21,22).
In this study, we compared the risk of congenital
anomalies among pregnant women with hyperthyroidism
classified into three groups: those receiving PTU treatment,
those receiving MMI treatment, and those receiving either
PTU or MMI first and then shifting to MMI or PTU,
respectively. In addition, we enrolled two control groups in
this study: completely healthy pregnant women and women
with hyperthyroidism who were not exposed to any ATD.
Severe hyperthyroidism during pregnancy typically causes
various complications for both the mother and the fetus (23).
Thus, the pregnant women who were not exposed to any
ATD either exhibited euthyroidism throughout pregnancy or
exhibited hyperthyroidism that was observed late in
pregnancy. The latter group of patients delivered before
therapy.
Compared with hyperthyroid women not receiving an
ATD or healthy pregnant controls, a significant increase in
the rate of major anomalies was observed in those receiving
MMI treatment. There was only a slight trend towards an
increased risk of congenital malformations in infants whose
mothers were treated with PTU compared with those whose
mothers were healthy controls. The risk of birth defects for
hyperthyroid women treated with PTU and those not
receiving any ATD was similar. As the non-exposed group
of women was largely healthy, the similar rates between the
two aforementioned groups indicated that PTU was the
Figure 1 - Flow chart of the literature search and article selection.
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Table 1 - Characteristics of the 7 studies included in the review.
Study Year Study
type
Participants Controls Treatment Birth defects
Andersen
et al.
2013 Cohort 1,661 women treated
with PTU or MMI
159 women who shifted
between MMI and
PTU treatment
811,730 women without
hyperthyroidism
3,543 women not
receiving any ATD
1,066 women without
hyperthyroidism
Treated with
antithyroid
medication in early
pregnancy
Urinary system malformation,
malformations in the face and
neck region, choanal atresia,
esophageal atresia
Chen et al. 2011 Case-
control
703 women treated with
PTU or MMI
14,150 women without
hyperthyroidism
2,127 women not
receiving any ATD
Treated with PTU or
MMI for at least
30 days
Cleft lip and palate, limb defects,
heart defects, Down syndrome,
hypospadias
Korelitz
et al.
2012 Case-
control
1,023 women treated
with PTU or MMI
126 women who shifted
between MMI and PTU
treatment
634,858 women without
hyperthyroidism
5,932 women not
receiving any ATD
Prescription (PTU or
MMI) filled within
the last 6 months of
pregnancy
Congenital anomalies of the eye,
complex heart anomalies, atrial
ventricular septal defects,
anomalies of the respiratory
system, anomalies of the
congenital organs
Rosenfeld
et al.
2009 Cohort 80 women treated with
PTU
1,066 women without
hyperthyroidism
Treated with PTU
between 4 and 13
weeks of gestation
Developmental dysplasia of the
hip
Yoshihara
et al.
2012 Case-
control
2,630 women treated
with PTU or MMI
1,906 women not
receiving any ATD
Treated with PTU or
MMI during the first
trimester
Aplasia cutis congenital, ompha-
locele, symptomatic ompha-
lomesenteric duct anomaly
Wing et al. 1994 Case-
control
135 women treated with
PTU or MMI
43 women not receiving
any ATD
99 women without
hyperthyroidism
Treated with PTU or
MMI
Severe pulmonary stenosis,
ventricular septal defect, patent
ductus arteriosus
Momotani
et al.
1984 Case-
control
117 women treated with
MMI
350 women without
hyperthyroidism
Treated with MMI
during the first
trimester
Malformation of the ear lobe,
omphalocele, imperforate anus,
anencephaly, harelip,
polydactyly
Figure 2 - Forest plot of the odds ratios and 95% confidence intervals of the pooled studies. (A) PTU-treated pregnant hyperthyroid
women compared with healthy pregnant women according to the risk of congenital anomalies. (B) PTU-treated pregnant hyperthyroid
women compared with pregnant hyperthyroid women not receiving any ATD treatment according to the risk of congenital anomalies.
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preferred option according to the risk of congenital anoma-
lies. However, one limitation to these studies was the
confounding between the effect of hyperthyroidism itself
and the effect of the drug in producing adverse fetal
outcomes. It is reasonable to expect that the more severe
examples of hyperthyroidism would be observed in the very
women for whom drug treatment was prescribed, particu-
larly at higher doses. Thus, the adverse fetal outcomes could
have resulted from either the underlying severe hyperthyr-
oidism or the treatment. To control for this confounding
factor, we considered the eligible subjects for this study to be
pregnant women with hyperthyroidism who received ATD
treatment. Then, we compared PTU use with MMI use in
relation to the overall rate of anomalies. Our data also
supported the use of PTU. Taken together, these results
indicated that PTU is a safer choice for the treatment of
pregnant women with hyperthyroidism according to the risk
of birth defects. This conclusion is in accordance with an
American Thyroid Association statement supporting the use
of PTU as the first-line agent for the management of
hyperthyroidism during pregnancy (24).
A recent systematic review conducted by Hackmon et al.
also described the safety of MMI and PTU during pregnancy
(25). These authors concluded that MMI is a teratogen, which
is consistent with our findings. In most cases associated with
MMI embryopathy included in the case reports reviewed by
Hackmon et al., exposure to MMI indeed occurred in the first
trimester during the critical embryogenic period. In the
present study, among the 6 studies examining the relation-
ship of MMI exposure to the risk of birth defects, a total of
Figure 3 - Forest plot of the odds ratios and 95% confidence intervals of the pooled studies. (A) MMI-treated pregnant hyperthyroid
women compared with healthy pregnant women according to the risk of congenital anomalies. (B) MMI-treated pregnant
hyperthyroid women compared with pregnant hyperthyroid women not receiving any ATD treatment according to the risk of
congenital anomalies.
Figure 4 - Forest plot of the odds ratios and 95% confidence intervals of the pooled studies comparing pregnant hyperthyroid women
who shifted between PTU and MMI with pregnant hyperthyroid women who did not receive any ATD treatment according to the risk
of congenital anomalies.
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3 studies (Anderson et al., Yoshihara et al., and Momotani
et al.) reported on the risk of congenital anomalies following
intrauterine exposure in the first trimester. The findings of
these studies showed that MMI treatment significantly
increased the risk of congenital malformations. The remain-
ing studies (Chen et al., Korelitz et al., and Wing et al), which
did not describe whether ATD treatment was administered
in the first trimester, failed to confirm a causal relationship
between MMI and congenital malformations. This result was
probably due to exposure after the period of organogenesis.
Shifts between PTU and MMI are not common in the
treatment of patients with hyperthyroidism. Two of the
included articles did not explain the reason that the doctors
preferred to change the treatment, although this preference
was likely related to potential concerns about the teratogenic
effects of MMI in the first trimester and the hepatotoxicity of
PTU during pregnancy (26,27). Thus, it was suggested that in
pregnant women, PTU use should be restricted to the first
trimester, and MMI should then be used during the
remainder of pregnancy to minimize potential risks to the
fetus and the mother. Our study illustrated that shifts
between MMI and PTU may confer little protection against
birth defects. This conclusion is inconsistent with the
previous study conducted by Hackmon et al., who demon-
strated that PTU should be administered during the first
trimester, followed by a switch to MMI for the remainder of
the pregnancy. One possible explanation for this disagree-
ment might be as follows: due to severe PTU-induced
hepatotoxicity, women with hyperthyroidism might be
treated with MMI, and the shift from MMI to PTU may
only occur when they find out that they are pregnant. Thus,
there is a high probability that exposure to MMI occurs
during the critical embryogenic period (4 to 10 weeks)
because under most circumstances, women are actually
pregnant for more than one month before they find out that
they are pregnant. For instance, one study included in our
meta-analysis reported that the mean time from the begin-
ning of pregnancy to the shift to PTU treatment was 44 days.
In addition, considering shifts between PTU and MMI, there
were two types of drug prescription patterns observed in the
included studies: from PTU to MMI and from MMI to PTU.
Therefore, we should examine whether the prevalence of
birth defects differs according to type of ATD prescription
pattern.
However, there is no evidence from current trials to guide
the choice between PTU followed by a switch to MMI and
vice versa. Thus, it is certain that changes in ATD
prescription patterns are not necessary during pregnancy.
To avoid shifts in ATD use, it is recommended that women of
child-bearing age choose PTU treatment before pregnancy to
minimize the potential risk of congenital malformations.
Our research provides important population-based esti-
mates of medication use that are relevant to the care of
pregnant women with hyperthyroidism. However, a defini-
tive answer to this question remains unclear because there
are no available RCTs comparing antithyroid treatments in
pregnant women with hyperthyroidism. Additional human
epidemiology studies are needed, and new evidence-based
recommendations should be developed for the treatment of
women with hyperthyroidism during pregnancy.
Despite the lack of RCTs, we believe that our study
provides potentially useful data to physicians prescribing
ATDs to pregnant women with hyperthyroidism. The limited
available evidence shows that PTU is a safer choice for
treating pregnant women with hyperthyroidism according to
the risk of birth defects but that shifting between MMI and
PTU fails to provide protection against birth defects.
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